Drug Profile
Hitanercept- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: Hitenercept; Recombinant human TNF receptor p75-Fc fusion protein - Shanghai Fudan-Zhangjiang; rhTNFR(m):Fc - Shanghai Fudan-Zhangjiang; T-0001 - Shanghai Fudan-ZhangjiangLatest Information Update: 06 Nov 2018
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 25 Oct 2018 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical terminates a phase I trial for Rheumatoid arthritis in China (NCT02481180)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in China (SC, Injection)